TELA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but lacks any earnings baseline for traditional valuation.
- Low P/S ratio (0.35)
- High P/B ratio (4.44) for a non-profitable firm
- No Graham Number due to negative earnings
Growth rates are positive but insufficient to offset the burn rate.
- Consistent revenue growth
- High analyst target price ($2.25)
- Growth is not translating to bottom-line improvement
- High risk of further dilution to fund operations
Historical performance is overwhelmingly negative across price and earnings.
- 95.4% loss over 5 years
- Consistent EPS misses
Severe distress; high debt levels make the company vulnerable to interest rate shifts or credit tightening.
- Strong current ratio
- Piotroski F-Score 1/9
- Debt/Equity 9.13
Non-dividend paying growth/distress stock.
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TELA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TELA
TELA Bio, Inc.
Primary
|
-95.4% | -93.3% | -29.1% | -57.4% | -18.9% | +12.7% |
|
AYTU
Aytu BioPharma, Inc.
Peer
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
|
KYNB
Kyntra Bio, Inc.
Peer
|
-98.6% | -98.5% | +10.3% | -32.0% | +0.7% | +2.3% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
|
ICCM
IceCure Medical Ltd
Peer
|
-97.0% | -71.2% | -71.9% | -62.9% | -51.7% | +7.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TELA
TELA Bio, Inc.
|
BEARISH | $28.23M | - | -223.4% | -48.4% | $0.63 | |
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | Compare |
|
KYNB
Kyntra Bio, Inc.
|
BEARISH | $29.02M | - | -% | 2848.6% | $7.17 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
|
ICCM
IceCure Medical Ltd
|
BEARISH | $26.25M | - | -188.8% | -% | $0.32 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-20 | TALMO PAUL | Chief Technology Officer | Stock Award | 57,000 | - |
| 2026-02-20 | FIRESTONE GREGORY A | Officer | Stock Award | 37,000 | - |
| 2026-02-20 | BLIZARD JEFFREY | President | Stock Award | 86,000 | - |
| 2026-02-20 | KOBLISH ANTONY | Chief Executive Officer | Stock Award | 176,000 | - |
| 2026-02-20 | CUCA ROBERTO | Chief Operating Officer | Stock Award | 57,000 | - |
| 2026-02-18 | SMEYKAL MEGAN | Officer | Stock Award | 32,850 | - |
| 2025-11-17 | EW HEALTHCARE PARTNERS FUND 2, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 3,604,000 | $4,000,440 |
| 2025-10-31 | PLOVANIC WILLIAM J. | Director | Stock Award | 11,925 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TELA from our newsroom.